CA
NZ
UK
AU
IND
US
• No ARIA-E Observed at 12 Months: The 12-month ABATE interim data showed a favorable safety profile with no observed Amyloid-Related Imaging Abnormalities — Edema, a key safety concern in Alzheimer's immunotherapy.
• FDA CRL Cites Manufacturing Only: The Complete Response Letter identified unresolved issues at a third-party manufacturing facility with no concerns raised about clinical data or safety.
• Primary Endpoint Not Met: Fasedienol showed an LS mean SUDS change of -9.5 versus -11.4 for placebo, a statistically insignificant result with p=0.427.
• 37.2% of Non-Responders Achieved Remission: Patients who failed induction had a 37.2% clinical remission rate in the ABTECT Maintenance Part 2 study, a meaningful result for a refractory population.
• Roth Capital Raises Target to $130: The firm increased its price target from $100 while maintaining a Buy rating, citing the transformative Iridium acquisition.
• Wedbush Initiates at Outperform: Analyst Sam Brandeis started coverage with a $190 price target, calling SpaceX "one of the most differentiated assets" in tech.
• BofA Raises Target to $36: Bank of America increased its price target to $36 from $25 while maintaining a Neutral rating, citing improving prescription trends.
• UBS Upgrades to Buy: Analyst Kaio Prato upgraded DLocal to Buy from Neutral with a $20 price target, up from $16.
• DRAM and NAND Both Quadrupled: Both major memory chip categories have seen prices quadruple over the past year, driven by AI data center demand.
• Goldman Sachs Raises Target to $121: Analyst James Yaro increased the price target from $108 while maintaining a Buy rating.
Please wait processing your request...